Drug Tariffs: US Prices & Supply Impact
- President Donald Trump's proposed pharmaceutical tariffs, intended to stimulate U.S.
- Mariana Socal, MD, PhD, and Jeromie Ballreich, PhD, associate professors at the Johns Hopkins Bloomberg School of Public Health in Baltimore, addressed the potential consequences during a recent...
- While pharmaceuticals are currently exempt from tariffs, Trump has repeatedly stated his intention to impose them.
President Trump’s proposed drug tariffs could significantly impact American consumers and the pharmaceutical industry. Experts warn that these tariffs, intended to boost U.S. manufacturing, may inadvertently hike drug prices and restrict access to vital medications, including both brand-name and generic options. The shift of pharmaceutical manufacturing overseas, primarily due to tax advantages, adds further complexity. Potential tariffs of 25-50% could hit Medicare and consumers, exacerbating existing affordability issues. Generic drug shortages are also a major concern, with tariffs potentially worsening the supply crisis. As News Directory 3 explores, the repercussions are far-reaching, including impacts on domestic production and pharmaceutical imports. Reassessing tax policies could be a viable option while the public waits.Discover what’s next for drug pricing and availability.
Trump tariffs Could Hike Drug Prices, Experts Warn
President Donald Trump’s proposed pharmaceutical tariffs, intended to stimulate U.S. manufacturing and national security, may backfire, leading to increased costs and reduced access to both brand-name and generic medications, according to health policy specialists.
Mariana Socal, MD, PhD, and Jeromie Ballreich, PhD, associate professors at the Johns Hopkins Bloomberg School of Public Health in Baltimore, addressed the potential consequences during a recent press briefing. They highlighted the complex interplay of factors influencing drug prices and availability, emphasizing the potential for unintended consequences.
While pharmaceuticals are currently exempt from tariffs, Trump has repeatedly stated his intention to impose them. Ballreich noted that while branded pharmaceuticals account for only 15% of U.S. prescriptions, they represent nearly 90% of spending. He added that much of the manufacturing has moved overseas in the last two decades, primarily to countries like Switzerland, Ireland, and Germany, for tax advantages, not lower labor costs.
Socal said the U.S. already pays three to four times more for branded drugs than other developed nations, leading to affordability issues for many Americans. “About 1 in 4 Americans report not being able to afford the medications they need,” Socal said. “If tariffs are applied to prescription drugs, one of the most immediate consequences could be price increases.”
The generic drug market faces different challenges. Socal explained that the primary concern isn’t cost, but supply shortages. Hospitals frequently struggle to find necessary medications. Tariffs on generics could worsen these shortages, as lower profit margins and lack of patent protection may discourage production.
Ballreich estimated potential tariffs could range from 25% to 50%. “We expect these tariffs to be passed on to the Medicare program, and ultimately patients will either pay more at the pharmacy or face higher Medicare Part D premiums,” he said.
Anticipating potential tariffs, pharmaceutical imports have already surged. Ballreich noted a fivefold increase in U.S. imports from Ireland, the largest source of branded pharmaceuticals, in March year-over-year.
Socal acknowledged that the U.S. maintains drug stockpiles, but primarily for bioterrorism or acute emergencies. While hospital stockpiling has been suggested, its scope remains unclear. “We cannot have stockpiles over stockpiles for every single drug,” Socal said. “Policies to resolve supply disruptions and shortages should be the way to go.”
Socal also pointed to the Inflation Reduction Act of 2022,which penalizes manufacturers for raising prices faster than inflation. She warned that this “can have an unintended outcome. If the manufacturer cannot raise prices because the penalty might be too high, one of the possibilities is that the manufacturer may simply want to discontinue a drug.”
When asked about scaling up domestic drug production, Ballreich said it would take ”years.” He emphasized the complexity of biologics compared to small-molecule drugs. “I don’t think we’re going to see a significant surge in domestic or US manufacturing of branded pharmaceuticals in the near term, that is, within the next year or 2,” he said.
Ballreich suggested reassessing tax policy to encourage manufacturers to locate within the U.S. Socal added that even domestic manufacturers rely on foreign ingredients, and tariffs could make them less competitive globally.
What’s next
The potential implementation of pharmaceutical tariffs remains uncertain. Experts will continue to monitor the situation and assess the potential impact on drug prices, availability, and the healthcare system.